ACXP

Bullish

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

Acurx Pharmaceuticals (ACXP) reported a Q1 2026 net loss of $1.7 million, narrowing from $2.1 million, with cash increasing to $9.3 million. The compa...

Stock Titan 17 hours ago 0

Neutral

Acurx Pharmaceuticals (ACXP) director receives 2,150 stock options grant

Joseph C. Scodari, a director at Acurx Pharmaceuticals (ACXP), has been granted 2,150 stock options as compensation for his board service. The options...

Stock Titan 2 weeks ago 0